Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of PM8002 Injection Plus Nab-paclitaxel as First Line Therapy for Unresectable, Locally Advanced or Metastatic Triple-negative Breast Cancer

NCT05918133 is registered in ClinicalTrials.gov with Biotheus Inc. as lead sponsor.

NCT NCT05918133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05918133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of PM8002 Injection Plus Nab-paclitaxel as First Line Therapy for Unresectable, Locally Advanced or Metastatic Triple-negative Breast Cancer
Lead sponsor
Biotheus Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 1, 2022
Completion date
October 30, 2026
Enrollment
42 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

tnbc